Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Cutting-Edge Cell & Gene Therapy Manufacturing Center, BioCentriq™, Opens in Newark, New Jersey

Virtual ribbon cutting and tour featured remarks from New Jersey Governor Phil Murphy, FDA's Peter Marks, as well as panel discussions with industry leaders from ARM, NIIMBL, Century Therapeutics, BioNJ, NJEDA, NJIT and NJII on the rise of Cell & Gene Therapy in New Jersey.


News provided by

New Jersey Innovation Insitute

Oct 29, 2020, 16:05 ET

Share this article

Share toX

Share this article

Share toX

BioCentriq Ribbon Cutting at NJIT Life Sciences & Engineering Center Building in Newark, NJ.
BioCentriq Ribbon Cutting at NJIT Life Sciences & Engineering Center Building in Newark, NJ.

NEWARK, N.J., Oct. 29, 2020 /PRNewswire-PRWeb/ -- The New Jersey Innovation Institute (NJII) and Choose New Jersey hosted a virtual ribbon cutting, tour and panel discussions to mark the opening of BioCentriq™, NJII's cutting-edge cell and gene therapy development and clinical manufacturing center located on the campus of the New Jersey Institute of Technology (NJIT) in Newark, New Jersey.

New Jersey Governor Murphy's pre-recorded opening remarks emphasized the important role centers of innovation like BioCentriq will play in a post-pandemic economy.

There is a massive need for what BioCentriq can provide, and our ability to fill that gap will translate into results that literally save and improve the quality of countless lives.

Post this

President of New Jersey Institute of Technology Dr. Joel Bloom reinforced the governor's message by stating, "There is a massive need for what BioCentriq can provide, and our ability to fill that gap will translate into results that literally save and improve the quality of countless lives. We have the capacity to help companies develop processes, conduct clinical production trials, and train employees."

Jose Lozano, president and CEO of Choose New Jersey hosted the event.

"New Jersey is a top hub for cell and gene therapy," said Lozano. "We are home to groundbreaking cell and gene therapy companies that are leading the way in next-generation therapeutics. Today's ribbon cutting at BioCentriq is another exciting chapter for New Jersey's innovation economy. We look forward to seeing how BioCentriq will advance the industry in years to come."

Opening remarks were made by Joel Bloom, Ed.D. and president of NJIT, Governor Phil Murphy, Robert Cohen, president digital, robotics, and enabling technology at Stryker and Simon Nynens, CEO of NJII.

Pall Biotech, The National Institute for Innovation in Manufacturing Biopharmaceuticals, BMS, Cytiva, Panasonic Healthcare and Novartis were recognized, along with the 12 industry leaders who make up the biopharma advisory council, for their contributions of equipment, funding and expertise.

Dr. Peter Marks, MD., Ph.D., director of the center for biologics evaluation and research (CBER) at the U.S. Food and Drug Administration (FDA) spoke about the importance of cell and gene therapies and the role of the FDA in streamlining, removing hurdles and providing support to improve the availability of these therapies. He also talked about the importance of collaborative efforts like BioCentriq to help accelerate advancements and innovation.

Haro Hartounian, Ph.D. and SVP and GM of the Biopharma Division, and senior vice-president and general manager of BioCentriq, gave a detailed view of the new center and the work being done by the Biopharma division at NJII. Dr. Hartounian also premiered a video tour of the facility. In addition, he led a panel discussion on the future of cell and gene therapy manufacturing with Kelvin H. Lee, Ph.D. director of the National Institute for Innovation in Manufacturing (NIIMBL), Janet Lynch Lambert, CEO of the Alliance for Regenerative Medicine and Greg Russotti, Ph.D., chief technology officer of Century Therapeutics, LLC.

"BioCentriq's mission is to bring together industry, technology developers, academia and regulatory agencies to help advance the development and manufacturing of cell and gene therapies," said Dr. Hartounian. "We are thrilled to open the doors to our center at a time when demand for process development and clinical manufacturing of cell and gene therapies exceeds capacity available from existing contract development and manufacturing organizations. Our goal is to provide a collaborative space where innovative approaches and technologies can be utilized to help make emerging therapeutics available to the patients that so desperately need them."

The event concluded with a panel discussion that featured local leaders who described the resources New Jersey offers to companies who bring their cell and gene therapy projects and businesses to the state. Panelists included Debbie Hart, president & CEO of BioNJ; Jose Lozano; Kathleen Coviello, executive vice president for Technology, Life Sciences & Entrepreneurship at the New Jersey Economic Development Authority (NJEDA); and Kevin D. Belfield, Ph.D. and dean, College of Science & Liberal Arts, NJIT.

To learn more and view the recorded event please visit: https://www.choosenj.com/webinar/first-look-at-biocentriq/.

Shown in BioCentriq Ribbon Cutting at NJIT Life Sciences & Engineering Center Building in Newark, NJ photo from left to right are Robert Cohen, president, digital, robotics, and enabling technology, Stryker, Simon Nynens, CEO, New Jersey Innovation Institute (NJII), Joel Bloom, Ed.D., president, New Jersey Institute of Technology (NJIT), Dan Wessner, director of sales, Pall Biotech, Haro Hartounian, Ph.D., SVP and general manager, NJII, Fadi P. Deek, Ph.D., provost and senior executive vice president, NJIT and Jose Lozano, president & CEO, Choose New Jersey.

SOURCE New Jersey Innovation Insitute

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.